Yeung Melissa Y, Gabardi Steven, Sayegh Mohamed H
a Transplantation Research Center, Renal Division , Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States.
b Faculty of Medicine, Professor of Medicine and Immunology , American University of Beirut , Beirut , Lebanon.
Expert Opin Biol Ther. 2017 Mar;17(3):339-352. doi: 10.1080/14712598.2017.1283400. Epub 2017 Jan 30.
For over thirty years, antibody (mAb)-based therapies have been a standard component of transplant immunosuppression, and yet much remains to be learned in order for us to truly harness their therapeutic capabilities. Current mAbs used in transplant directly target and destroy graft-destructive immune cells, interrupt cytokine and costimulation-dependent T and B cell activation, and prevent down-stream complement activation. Areas covered: This review summarizes our current approaches to using antibody-based therapies to prevent and treat allograft rejection. It also provides examples of promising novel mAb therapies, and discusses the potential for future mAb development in transplantation. Expert opinion: The broad capability of antibodies, in parallel with our growing ability to synthetically modulate them, offers exciting opportunities to develop better biologic therapeutics. In order to do so, we must further our understanding about the basic biology underlying allograft rejection, and gain better appreciation of how characteristics of therapeutic antibodies affect their efficacy.
三十多年来，基于抗体（单克隆抗体）的疗法一直是移植免疫抑制的标准组成部分，然而，为了真正发挥其治疗能力，仍有许多需要了解的地方。目前用于移植的单克隆抗体直接靶向并破坏破坏移植物的免疫细胞，中断细胞因子以及共刺激依赖性T细胞和B细胞的激活，并防止下游补体激活。涵盖领域：本综述总结了我们目前使用基于抗体的疗法预防和治疗同种异体移植排斥反应的方法。它还提供了有前景的新型单克隆抗体疗法的实例，并讨论了移植中未来单克隆抗体开发的潜力。专家观点：抗体的广泛能力，与我们日益增长的合成调节它们的能力相结合，为开发更好的生物疗法提供了令人兴奋的机会。为了做到这一点，我们必须进一步了解同种异体移植排斥反应背后的基本生物学，并更好地理解治疗性抗体的特性如何影响其疗效。
